Entero Therapeutics (NASDAQ:ENTO) Shares Down 2% – Should You Sell?

Entero Therapeutics, Inc. (NASDAQ:ENTO) shares traded down 2% on Tuesday . The company traded as low as $6.01 and last traded at $6.22. 40,935 shares were traded during mid-day trading, a decline of 99% from the average session volume of 2,798,922 shares. The stock had previously closed at $6.35.

Entero Therapeutics Stock Performance

The firm’s 50-day moving average is $3.40 and its 200 day moving average is $3.11. The firm has a market capitalization of $9.88 million, a PE ratio of -3.68 and a beta of 1.19.

Institutional Trading of Entero Therapeutics

An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned about 0.74% of Entero Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.